This is an international, multi-center, parallel group, event-driven, randomized, double-blind, placebo-controlled study in patients with chronic heart failure with reduced ejection fraction, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, for prevention of cardiovascular death or reduction of heart failure events.
CRITERIA LIST/ QUALIFICATIONS:
Reduced ejection fraction (<40%)
NYHA Class II-IV
On background standard of care heart failure medications